We also propose that the use of pharmacological or chemical inhibitors targeting HIF-1α and YY1 could be an alternative treatment for pediatric patients with ALL that are known to be positive for HIF-1α and YY1 expression, thus offering a therapeutic alternative for this disease. Here, YY1 is linked to acute lymphoblastic leukemia.